Special Issue "Antimicrobial Peptides as New Weapons to Fight Antimicrobial Resistance"
Deadline for manuscript submissions: 1 December 2021.
It has been extensively reported that prolonged exposure to antibiotics is responsible for the development of multidrug resistant organisms (MDROs). Indeed, over the past four decades, there has been an explosion of so-called “superbugs”, such as vancomycin-resistant enterococci (VRE) and multidrug-resistant Pseudomonas, Klebsiella, and Acinetobacter bacterial strains. It is also known that microbes in a biofilm community gain additional antibiotic resistance that can be up to 1000 times higher than that gained by the corresponding planktonic cells. Therefore, the emergence of resistance to multiple antimicrobial agents has become a serious public health threat with great social and economic impacts. It should also be highlighted that the discovery, development, manufacture, and marketing of new antibiotics has significantly slowed down in the past 20 years. Thus, effective alternative strategies to conventional antibiotics are urgently needed. Consequently, naturally occurring host defence peptides (HDPs), first called antimicrobial peptides (AMPs), have attracted considerable attention because of their antimicrobial, anti-biofilm, and immunomodulatory properties but, above all, because they generally do not lead to selection of resistant strains, since this would require an almost complete remodeling of the bacterial membrane architecture. To date, over 1700 endogenous antimicrobial peptides have been isolated, with even more synthetic analogues reported in the literature. Because of their diverse spectrum of activity against microbial pathogens, both as innate defence molecules and as immunomodulators, HDPs are attractive candidates for the development of a new generation of antibiotics. This Special Issue has the aim of summarizing the state of the art and the latest findings published in the field of antimicrobial peptides, as well as elucidating future directions of research.
Dr. Angela Arciello
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Antimicrobial peptides
- Antimicrobial resistance
- Peptide-based drugs
- Antibiofilm peptides